2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
https://www.fool.com/investing/2023/12/31/gene-editing-stocks-that-might-be-the-next-crispr/?source=iedfolrf0000001
Dec 31, 2023 - Curing rare inherited illnesses could be a lucrative business model.
0
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
https://www.fool.com/investing/2023/12/31/1-cathie-wood-stock-worth-buying-hand-over-fist-in/?source=iedfolrf0000001
Dec 31, 2023 - Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.
0
bluebird (BLUE) Down Despite FDA Nod to Gene Therapy for SCD
https://www.zacks.com/stock/news/2196255/bluebird-blue-down-despite-fda-nod-to-gene-therapy-for-scd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196255
Dec 11, 2023 - bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.
0
CRISPR (CRSP), Vertex Fall Despite FDA Nod to SCD Drug Casgevy
https://www.zacks.com/stock/news/2196180/crispr-crsp-vertex-fall-despite-fda-nod-to-scd-drug-casgevy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196180
Dec 11, 2023 - CRISPR (CRSP) and Vertex announce the FDA approval of the first-ever CRISPR-based gene-editing therapy, Casgevy, for the treatment of sickle cell disease.
0
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
https://www.zacks.com/stock/news/2197830/vertex-vrtx-hits-record-high-on-non-opioid-pain-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197830
Dec 14, 2023 - Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
0
Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy
https://www.zacks.com/stock/news/2199442/vertex-vrtx-crispr-get-positive-chmp-opinion-for-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199442
Dec 18, 2023 - Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.
0
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
https://www.zacks.com/stock/news/2199324/3-biotech-stocks-most-wall-street-analysts-are-bullish-about?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199324
Dec 18, 2023 - Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
0
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
https://www.zacks.com/stock/news/2211622/vertex-vrtx-crsp-s-casgevy-gets-fda-nod-for-thalassemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211622
Jan 17, 2024 - This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
0
Charles River (CRL) Forges Collaboration With Ship of Theseus
https://www.zacks.com/stock/news/2253832/charles-river-crl-forges-collaboration-with-ship-of-theseus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253832
Apr 11, 2024 - Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
0
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
https://www.zacks.com/stock/news/2256355/bluebird-blue-underperforms-industry-ytd-amid-challenges?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2256355
Apr 16, 2024 - bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
0
<Page 2